Transarterial Radioembolization: A New Selection to Treat Hepatocellular Carcinoma

  •  Haipeng Yu    
  •  Zhi Guo    
  •  Changfu Liu    
  •  Tonguo Si    
  •  Xueling Yang    
  •  Weihao Zhang    
  •  Yan Xu    
  •  Yong Li    


With the development of the material science, the clinical application of stable nuclide microspheres has become a hot spot of endovascular treatment of liver cancer in last 10 years. Transarterial radioembolization came to be a new selection to treat hepatocellular carcinoma. The characteristics of the radioactive microsphere determine obvious different between TARE and TACE. For early HCC, TARE as the degradation treatment or transition treatment waiting for liver transplantation.For advanced HCC, TARE as the treatment of unresectable advanced hepatocellular cancer. TARE as the rescue treatment of recurrence after liver resection. TARE as a treatment of HCC with portal vein tumor thrombus. How to make more patients in Asia countries such as China benefit, the optimization of treatment, indications of therapy, radioactive microsphere local production, health economics studies, all needed to further research.

This work is licensed under a Creative Commons Attribution 4.0 License.
  • ISSN(Print): 1916-9698
  • ISSN(Online): 1916-9701
  • Started: 2009
  • Frequency: semiannual

Journal Metrics

h-index (December 2022): 32

i10-index (December 2022): 145

h5-index (December 2022): N/A

h5-median(December 2022): N/A

( The data was calculated based on Google Scholar Citations. Click Here to Learn More. )